{
    "organizations": [],
    "uuid": "ab38e6b2b0e4a115cbbbbb785589c6de43623f5d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-opiant-pharma-announces-positive-d/brief-opiant-pharma-announces-positive-data-from-a-phase-i-clinical-study-of-opnt003-idUSFWN1Q20UJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 21 PM / in 13 minutes BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003 Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Opiant Pharmaceuticals Inc: \n* OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003 \n* OPIANT PHARMACEUTICALS INC - ANTICIPATES TO SUBMIT A NEW DRUG APPLICATION FOR DRUG AND INTRANASAL DELIVERY DEVICE COMBINATION IN 2020 \n* OPIANT PHARMACEUTICALS INC - ANTICIPATE SUBMITTING AN NDA FOR OPNT003 IN 2020 \n* OPIANT - HAS FULL COMMERCIAL RIGHTS TO OPNT003; SUBMITTED GRANT APPLICATION TO NATIONAL INSTITUTES OF HEALTH TO FUND DEVELOPMENT TO NDA READY STAGE Source text for Eikon:  ",
    "published": "2018-02-12T15:19:00.000+02:00",
    "crawled": "2018-02-12T15:48:13.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "pharma",
        "announces",
        "positive",
        "data",
        "phase",
        "clinical",
        "study",
        "opnt003",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "opiant",
        "pharmaceutical",
        "inc",
        "opiant",
        "pharmaceutical",
        "inc",
        "announces",
        "positive",
        "data",
        "phase",
        "clinical",
        "study",
        "product",
        "candidate",
        "opnt003",
        "opiant",
        "pharmaceutical",
        "inc",
        "anticipates",
        "submit",
        "new",
        "drug",
        "application",
        "drug",
        "intranasal",
        "delivery",
        "device",
        "combination",
        "opiant",
        "pharmaceutical",
        "inc",
        "anticipate",
        "submitting",
        "nda",
        "opnt003",
        "opiant",
        "full",
        "commercial",
        "right",
        "opnt003",
        "submitted",
        "grant",
        "application",
        "national",
        "institute",
        "health",
        "fund",
        "development",
        "nda",
        "ready",
        "stage",
        "source",
        "text",
        "eikon"
    ]
}